Please ensure Javascript is enabled for purposes of website accessibility

Why Novavax Stock Is Jumping Today

By Keith Speights - Updated Feb 5, 2021 at 11:16AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech announced the start of a rolling review process for its COVID-19 vaccine in several countries.

What happened

Shares of Novavax (NVAX 17.46%) were jumping 4.4% as of 10:59 a.m. EST on Friday after rising as much as 6.8% earlier in the day. The gain came after the biotech announced the start of a rolling review by several regulatory agencies for potential authorization of its COVID-19 vaccine candidate, NVX-CoV2373. 

So what

Today's jump appears to be warranted, with Novavax moving another step closer to potentially being able to market its COVID-19 vaccine. The company announced great interim results in late January from a U.K. phase 3 study. It makes sense that Novavax moved quickly to seek authorizations in the U.K. and other countries based on this data.

Healthcare worker holding a syringe with needle and a vaccine vial

Image source: Getty Images.

Novavax said that the European Medicines Agency, the Food and Drug Administration, the U.K. Medicines and Healthcare products Regulatory Agency, and Health Canada have started the rolling review process for Emergency Use Authorization (EUA) of NVX-CoV2373.

Perhaps the only surprise on the list is the FDA, which typically requires results from U.S. clinical trials. Novavax began a late-stage study of NVX-CoV2373 in the U.S. and Mexico near the end of 2020. 

Now what

Based on the overwhelmingly positive results from Novavax's U.K. study, the chances of NVX-CoV2373 winning authorizations soon in the U.K., Europe, and Canada appear to be good. Any of these authorizations would provide a nice catalyst for the biotech stock

It's uncertain as to whether or not the FDA can be convinced to allow Novavax to use its British data for an EUA filing in the U.S., though. Novavax might have to wait a few months before it can launch NVX-CoV2373 in the states.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
$55.29 (17.46%) $8.22

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.